



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
ASSISTANT SECRETARY OF COMMERCE AND
COMMISSIONER OF PATENTS AND TRADEMARKS
P. O. Box 1450
Alexandria, VA 22313-1450

RP
3/24/06

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
10/084,400	2-20-02	Meade, Harry	10275-041002

EXAMINER	
Joseph T. Wootach	
ART UNIT	PAPER NUMBER
1632	

Date: 3-21-06
To: Byron V. Olseal
Fax: 508-370-3797
Phone: 508-370-5150

STATUS LETTER

(Transmitted by facsimile - no cover sheet)

In response to your communication filed on 3-03-06:

- ☐ 1. A Notice of Allowance for the above identified application was mailed on _____.
- ☐ 2. The above identified application has been assigned a patent number and issue date. An issue notification will be mailed within _____ weeks.
- ☐ 3. The above identified application has been assigned a patent number _____ and issue date _____.
- ☐ 4. Your application is currently located in _____. Please call 703/571 _____ to make further inquiries.
- ☒ 5. This Application will be sent to
EADC shortly to be scanned

If you have any questions, you may contact the Office of Patent Publication's Customer Service Office on 571-272-4200 or by facsimile on _____.

Contact Representative, Customer Service Office
Office of Patent Publication



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Young et al.

Art Unit No.: 1632

Application No.: 10/081,400

Examiner: Joseph T. Woitach

Filed: February 20, 2002

For: ERYTHROPOIETIN ANALOG-HUMAN SERUM ALBUMIN FUSION

Attorney Docket Number: GTC-6D

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

STATUS INQUIRY

Dear Sir:

Applicant respectfully inquires as to the status of the above application. The application was filed on February 20, 2002. Per the office action issued September 19, 2005, the application's last known status was "*application is in condition for allowance except for formal matters, prosecution on the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.*" On December 22, 2005 Applicants filed a Response to Notice of Non-Compliant Amendment for purposes of correcting the CRF relative to this application and correcting SEQ ID No. 3 in the Sequence Listing. Applicant's prior response of September 29, 2005 addressed and corrected other formal matters regarding sequence compliance. Applicant's request a status update with regard to receipt of the Notice of Allowance for allowed claims 53-72.

Respectfully submitted,

3/8/2006
Date

By:

Byron V. Olsen, Attorney for Applicants
Registration Number 42,960
GTC Biotherapeutics, Inc.
175 Crossing Boulevard, Suite 410
Framingham, MA 01702
Phone: 508-370-5150 Fax: 508-370-3797

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify that under 37 CFR §1.8(a) that this correspondence is being deposited on March 7, 2006 with the United States Postal Service as first class mail with sufficient postage in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dawn C. Greenaway